よむ、つかう、まなぶ。
資料4-5 メトホルミン塩酸塩 (33 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00022.html |
| 出典情報 | 医薬・生活衛生局が実施する検討会 医療上の必要性の高い未承認薬・適応外薬検討会議（第50回 1／26）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
review and network meta-analysis. BMJ. 2017;356:j138.
41） Ng EH, et al. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women
with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled
trial. Hum Reprod. 2001; 16: 1625-31.
42） Siebert TI, et al. Is the addition of metformin efficacious in the treatment of clomiphene citrateresistant patients with polycystic ovary syndrome? A structured literature review. Fertil Steril.
2006; 86: 1432-7.
43） International evidence-based guideline for the assessment and management of polycystic ovary
syndrome 2018.
44） Morley LC, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiroinositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Cochrane Database Syst Rev. 2017; 11: CD003053.
45） Onalan G, et al. Predictive value of glucose-insulin ratio in PCOS and profile of women who
will benefit from metformin therapy: obese, lean, hyper or ormoinsulinemic? Eur J Obstet
Gynecol Reprod Biol 2005; 123: 204-11.
46） Karimzadeh MA, et al. The effect of administration of metformin on lipid profile changes and
insulin resistance in patients with polycystic ovary syndrome. Middle East Fertil Soc J. 2007;
12: 174-8.
47） Basirat Z, et al. Enhanced ovarian folliclular development by metformin does not correlate with
pregnancy rate: a randomized trial. Int J Fertil Steril 2012: 6; 31-6.
48） Cheng J, et al. Clinical outcomes of ovulation induction with metformin, clomiphene citrate and
human menopausal gonadotrophin in polycystic ovary syndrome. J Int Med Res. 2010; 38: 12508.
49） Begum MR, et al. Pretreatment and co-administration of oral anti-diabetic agent with
clomiphene citrate or rFSH for ovulation induction in clomiphene-citrate-resistant polycystic
ovary syndrome. J Obstet Gynaecol Res 2013; 39: 966-73.
50） Liu C, et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women
with polycystic ovary syndrome: a prospective randomized trial. Glynecol Endocrinol. 2017; 33:
872-6.
51） Panchaud A, et al. Use of metformin during pregnancy and risk of major congenital
malformations: Preliminary findings of a systematic review and meta-analysis. Reprod Toxicol
2019; 88; 149.
52） Diav-Citrin O, et al. In-utero exposure to metformin for type 2 diabetes or polycystic ovary
syndrome: A prospective comparative observational study. Reprod Toxicol 2018; 80: 85-91.
53） Scherneck S, et al. Pregnancy outcome after first-trimester exposure to metformin: A
prospective cohort study. Reprod Toxicol 2018; 81; 79-83.
54） Gilbert C, et al. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis.
33
41） Ng EH, et al. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women
with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled
trial. Hum Reprod. 2001; 16: 1625-31.
42） Siebert TI, et al. Is the addition of metformin efficacious in the treatment of clomiphene citrateresistant patients with polycystic ovary syndrome? A structured literature review. Fertil Steril.
2006; 86: 1432-7.
43） International evidence-based guideline for the assessment and management of polycystic ovary
syndrome 2018.
44） Morley LC, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiroinositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Cochrane Database Syst Rev. 2017; 11: CD003053.
45） Onalan G, et al. Predictive value of glucose-insulin ratio in PCOS and profile of women who
will benefit from metformin therapy: obese, lean, hyper or ormoinsulinemic? Eur J Obstet
Gynecol Reprod Biol 2005; 123: 204-11.
46） Karimzadeh MA, et al. The effect of administration of metformin on lipid profile changes and
insulin resistance in patients with polycystic ovary syndrome. Middle East Fertil Soc J. 2007;
12: 174-8.
47） Basirat Z, et al. Enhanced ovarian folliclular development by metformin does not correlate with
pregnancy rate: a randomized trial. Int J Fertil Steril 2012: 6; 31-6.
48） Cheng J, et al. Clinical outcomes of ovulation induction with metformin, clomiphene citrate and
human menopausal gonadotrophin in polycystic ovary syndrome. J Int Med Res. 2010; 38: 12508.
49） Begum MR, et al. Pretreatment and co-administration of oral anti-diabetic agent with
clomiphene citrate or rFSH for ovulation induction in clomiphene-citrate-resistant polycystic
ovary syndrome. J Obstet Gynaecol Res 2013; 39: 966-73.
50） Liu C, et al. Comparison of clomiphene citrate and letrozole for ovulation induction in women
with polycystic ovary syndrome: a prospective randomized trial. Glynecol Endocrinol. 2017; 33:
872-6.
51） Panchaud A, et al. Use of metformin during pregnancy and risk of major congenital
malformations: Preliminary findings of a systematic review and meta-analysis. Reprod Toxicol
2019; 88; 149.
52） Diav-Citrin O, et al. In-utero exposure to metformin for type 2 diabetes or polycystic ovary
syndrome: A prospective comparative observational study. Reprod Toxicol 2018; 80: 85-91.
53） Scherneck S, et al. Pregnancy outcome after first-trimester exposure to metformin: A
prospective cohort study. Reprod Toxicol 2018; 81; 79-83.
54） Gilbert C, et al. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis.
33